Acute promyelocytic leukemia (APL) is characterized by a specific chromosome translocation involving RAR␣ and one of four fusion partners: PML, PLZF, NPM, and NuMA genes. To study the leukemogenic potential of the fusion genes in vivo, we generated transgenic mice with PLZF-RAR␣ and NPM-RAR␣. PLZF-RAR␣ transgenic animals developed chronic myeloid leukemia-like phenotypes at an early stage of life (within 3 months in five of six mice), whereas three NPM-RAR␣ transgenic mice showed a spectrum of phenotypes from typical APL to chronic myeloid leukemia relatively late in life (from 12 to 15 months). In contrast to bone marrow cells from PLZF-RAR␣ transgenic mice, those from NPM-RAR␣ transgenic mice could be induced to differentiate by all-trans-retinoic acid (ATRA). We also studied RARE binding properties and interactions between nuclear corepressor SMRT and various fusion proteins in response to ATRA. Dissociation of SMRT from different receptors was observed at ATRA concentrations of 0.01 M, 0.1 M, and 1.0 M for RAR␣-RXR␣, NPM-RAR␣, and PML-RAR␣, respectively, but not observed for PLZF-RAR␣ even in the presence of 10 M ATRA. We also determined the expression of the tissue factor gene in transgenic mice, which was detected only in bone marrow cells of mice expressing the fusion genes. These data clearly establish the leukemogenic role of PLZF-RAR␣ and NPM-RAR␣ and the importance of fusion receptor͞corepressor interactions in the pathogenesis as well as in determining different clinical phenotypes of APL.
Acute promyelocytic leukemia (APL) is characterized in most patients by accumulation of promyelocytes containing a specific chromosomal translocation t(15;17) and a unique sensitivity to all-trans-retinoic acid (ATRA) treatment (1, 2) . There have been three variant translocations reported, including t(11;17)(q23;q21), t(5;17)(q32;q21), and t(11;17)(q13;q21). These chromosomal translocations invariably involve the RAR␣ (retinoic acid receptor ␣) gene on chromosome 17, and the PML (promyelocytic leukemia), PLZF (promyelocytic leukemia zinc finger), NPM (nucleophosmin), and NuMA (nuclear mitotic apparatus protein) genes on chromosomes 15q22, 11q23, 5q32, and 11q13, respectively (3) (4) (5) (6) (7) (8) (9) (10) . The breakpoints in the RAR␣ gene are always fixed, regardless of its fusion partner; therefore, RAR␣ retains the same functional domains (B-F), including the DNA, corepressor͞coactivator, and ligand binding regions in all fusion proteins (11, 12) . RARs are transcription factors that bind to RAREs (retinoic acid response elements) in a heterodimer formed with RXRs (retinoic X receptors; refs. 13, 14) . In the absence of ATRA, RAR␣͞RXR␣ is associated with a nuclear corepressor composed of N-CoR (nuclear receptor corepressor) or SMRT (silencing mediator for retinoid and thyroid-hormone receptors), Sin3A or Sin3B, and histone deacetylase HDAC1 or HDAC2, thus inhibiting transcription of ATRA-responsive genes. ATRA dissociates corepressors from and recruits coactivators to RAR␣͞RXR␣, resulting in transcription of RAREresponsive genes and subsequent induction of cell differentiation and growth arrest (15, 16) .
PML-RAR␣, PLZF-RAR␣, and NPM-RAR␣ (hereafter, together these are referred to as X-RAR␣) fusion proteins have the same RAR␣ part but differ in the X moiety. PML is a member of the RING finger family, which may have growth suppressor activity (5, 12) . PLZF is a phosphoprotein with an N-terminal BTB͞POZ (Pox-virus and zinc finger) domain and a C-terminal Kruppel DNA binding domain (6, 7) . PML and PLZF show similar nuclear distribution in structures known as nuclear bodies, whereas expression of PML-RAR␣ fusion protein disrupts the normal subcellular localization of PML, which could be restored by an effect of ATRA (17) (18) (19) . NPM is a major nonribosomal nucleolar phosphoprotein that is also implicated in a number of other malignancies (8, 12) . Patients with APL with different fusions are clinically indistinguishable, except that patients with PLZF-RAR␣ fusion are resistant to ATRA treatment (20) (21) (22) . A number of studies have confirmed the leukemogenic role of PML-RAR␣ (23) (24) (25) (26) (27) (28) . In an attempt to define the leukemogenic potential of variant fusion genes, we generated transgenic mice with PLZF-RAR␣ and NPM-RAR␣. Consistent with a recent report (29) , PLZF-RAR␣ transgenic mice had leukemia phenotypes different from those of PML-RAR␣. Transforming activity of NPM-RAR␣ fusion gene, on the other hand, was identified in transgenic animals. As part of the phenotype analysis, we also determined the expression of the tissue factor (TF) gene, which has been considered to be involved in the pathogenesis of coagulopathies typical of APL (30, 31) .
Both PML-RAR␣ and PLZF-RAR␣ bind to RAREs as homodimers or in a complex with RXR␣ (32) . Previous studies have shown that these two fusion proteins have ligand-binding affinities similar to the wild-type molecule RAR␣͞RXR␣ and
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PNAS is available online at www.pnas.org. can form a complex with nuclear corepressors. In interacting with nuclear corepressors, however, these fusion proteins have different ligand sensitivities, which may be the underlying molecular mechanism for differential responses to ATRA (15, 16, 33, 34) . To understand better the molecular mechanisms underlying APL pathogenesis and response to ATRA, we addressed the interactions between NPM-RAR␣ and nuclear corepressor in response to ATRA in comparison with RAR␣͞RXR␣, PML-RAR␣, and PLZF-RAR␣.
MATERIALS AND METHODS

Construction of Transgenes.
Both PLZF-RAR␣ and NPM-RAR␣ fusion gene cDNAs were PCR amplified and cloned into the pUC9-hCG vector (kindly provided by Timothy J. Ley, Washington University Medical School, St. Louis) by using restriction sites ClaI and NotI. Transgenic mice (C57) were generated by using the purified transgene fragments as described (26) . Constructs also were made in which the expression of PLZF-RAR␣ was driven by simian virus 40 (SV40) or cytomegalovirus (CMV).
Detection of Transgene Integration͞Expression and TF Gene Expression. The murine genomic DNA was isolated from tail tissue. Integration of the transgenes was detected by PCR and Southern blot analysis. Primers were designed to amplify fragments spanning the breakpoints of PLZF-RAR␣ and NPM-RAR␣ cDNAs, respectively. Total RNA was extracted from bone marrow (BM) cells of transgenic mice. Expression of the transgenes was detected by a nested reverse transcription-PCR (RT-PCR) approach, by using two pairs of primers spanning the first intron of hCG (26, 29) . RT-PCR primers were designed for the detection of mouse TF gene expression according to its mRNA sequence (35) .
Morphological and Histochemical Analyses. Peripheral blood smears or BM cells prepared by using conventional methods were stained with Wright's Giemsa. Sections (4-m thick) of a frozen spleen or liver from a transgenic or nontransgenic mouse were stained histochemically with the Wright's Giemsa or the myeloperoxidase. Femurs, spleens, or livers from either transgenic or nontransgenic mice were isolated, fixed in 10% formalin, and subsequently embedded in paraffin. Paraffin was then removed from the 4-m-thick sections, and they were stained with hematoxylin and eosin.
Immunofluorescence. BM and spleen cells were fixed with 4% paraformaldehyde for 10 min and made permeable with methanol at Ϫ20°C for 7 min. The cells were incubated subsequently with a primary PLZF antibody (29) .
ATRA Treatment of BM Cells. BM cells were isolated from transgenic leukemic mice before death. Cultures were performed at a cell concentration of 10 6 cells per ml in RPMI medium 1640 with or without ATRA at a final concentration of 1 M. Cells were harvested at 0, 24, 48 and 72 h for quantitative evaluation of differentiation induction and morphological studies.
Flow Cytometry. After blocking the murine FcII͞III receptors with an unlabeled FcR (CD16͞32) antibody, a single-cell suspension was incubated with Mac-1 (CD11b) antibody and Gr-1 (myeloid differentiation antigen) or c-Kit (CD117) antibodies. All antibodies were obtained from PharMingen. At least 1 ϫ 10 4 cells were analyzed from each sample on a FACScan flow cytometer (Becton Dickinson).
Expression Plasmids, in Vitro Translation and Gel-Shift Assay. The RAR␣, RXR␣, PML-RAR␣, PLZF-RAR␣, and NPM-RAR␣ expression vectors were constructed as described (32) . The RAR␣-specific binding sequence DR5G was end-labeled with [␥-32 P]ATP. The interactions between receptor proteins and DR5G as well as the specificity of the interactions were examined as described (32, 34) .
Glutathione S-Transferase (GST) Pull Down. To determine the interaction between various fusion proteins and nuclear receptor corepressor SMRT in response to ATRA, SMRT cDNA (kindly provided by Ronald Evans and J. Don Chen, University of Massachusetts, Worcester, MA) was inserted into a GST expression vector. GST-SMRT fusion protein was preincubated with glutathione Sepharose beads. After centrifugation and washing with cold PBS, [ 35 S]methionine-labeled receptor proteins were added and incubated with or without ATRA. Beads were then washed with buffer H (20 mM Hepes, pH 7.7͞50 mM KCl 20% (vol͞vol) glycerol ͞0.1% NP-40͞0.0007% ␤-mercaptoethanol). Bound proteins were eluted by boiling in sample buffer containing 10% SDS and resolved by SDS͞8% PAGE (15, 32) .
RESULTS
Generation of Transgenic Mice and Expression of Transgenes.
We generated 51 stable founder lines of hCG-PLZF-RAR␣ mice and 7 founder lines of hCG-NPM-RAR␣ mice (Table 1 ). Littermates that developed leukemic phenotypes all showed positive expression of the transgene in BM cells, whereas, in a total of 12 PLZF-RAR␣ lines randomly selected, 8 showed positive expression of the transgene in F 1 mice, and the other 4 were negative. Silencing or diminished expression of the integrated transgene may be due to nearby chromatin structure or other epigenetic factors caused by the integration. Most of the transgenic mice had normal development and fertility except those with an early onset of leukemia in the PLZF-RAR␣ group. Immunofluorescence analysis demonstrated that littermates expressing PLZF-RAR␣ fusion transcripts also had PLZF positive reactions in the cytoplasm of BM cells in a microgranular distribution. Of note, neither fusion gene expression nor leukemia phenotype was found in 9 lines of SV40-PLZF-RAR␣ and 16 lines of CMV-PLZF-RAR␣ over an observation period of 2 years.
Leukemia in PLZF-RAR␣ Transgenic Mice. Of the 51 founder line hCG-PLZF-RAR␣ mice, 6 developed leukemia phenotype; 5 of the 6 had short latent periods (31-85 days after birth), and 1 had a long latent period of 11 months. The five leukemic mice with early onset were characterized by low body weight (Fig. 1A) , marked splenomegaly, leukocytosis, increased percentage of mature myeloid cells, and myeloid͞lymphoid ratio in the peripheral blood and BM, resembling features of human chronic myeloid leukemia (CML), though promyelocytes also were present in significantly elevated percentages (Ϸ20%) in the BM (Table 2 ; Fig. 1C ). Histopathological analysis identified extreme expansion of myeloid cells at varying stages of maturation and disrupted BM trabeculae. Damage of splenic follicular architecture was observed, and the red pulp was infiltrated by myeloid cells, mainly myelocytes, metamyelocytes, and segmented forms (Fig. 1D) . Focal infiltration of liver with myeloid precursors also was observed, but the gross structure was unaffected (Fig. 1E) . The leukemia mouse with late onset presented with similar features, (1999) except that it developed normally until the onset of leukemia ( Table 2 , mouse no. 23).
Characteristics of NPM-RAR␣ Transgenic Mice. Of the hCG-NPM-RAR␣ mice, three developed leukemia, and another ( Table 2 , mouse no. 7) was killed when signs of disease were first observed; this mouse turned out to be still at the myelodysplasia-syndrome stage. There existed heterogeneity in cytology͞pathology in the three leukemic mice, with a spectrum of manifestations from typical APL to CML-like syndrome. Mouse no. 20 showed marked leukocytosis and increased percentages of both peripheral myeloid cells and myeloid͞lymphoid ratio; the morphology was typical of APL, with immature myeloid cells of enlarged cell volume and increased nucleus͞cytoplasm ratio (Fig. 1F) . Azurophilic granules that showed strong positive myeloperoxidase staining were apparent in the cytoplasm (Fig. 1G) . Mouse no. 16, in contrast, had CML features similar to PLZF-RAR␣ mice. Mouse no. 6 was characterized by myeloid cells with distorted nuclei, resembling the ''monocyte-like'' picture in some human APL. Splenomegaly was prominent in all three leukemic mice. Pathologically, in spite of distinct morphology, the red pulps were expanded and filled with large amount of myeloid cells, including myeloblasts, promyelocytes, and mature forms. Of note, in mouse no. 20, though disrupted splenic follicular 1H ) and BM trabeculae (not shown) were observed, no obvious hepatic infiltration was visible (Fig. 1I) .
Expression of TF Gene Was Correlated with Fusion Gene Expression.
To address the possible relationship between expression of TF and that of fusion genes, RT-PCR was performed on BM cells. As shown in Fig. 2 , in mice not expressing the fusion gene, TF was not detectable, whereas mice expressing either PLZF-RAR␣ or NPM-RAR␣ fusion gene invariably showed TF gene expression.
ATRA Sensitivity of BM Cells from Transgenic Mice. We assessed the ATRA responsiveness of BM myeloid precursors from NPM-RAR␣ transgenic mice at myelodysplasia-syndrome state (no. 7) and a leukemic PLZF-RAR␣ mouse (no. 23). BM cells were cultured in the absence or presence of 1 M ATRA for 24-72 h. In cell cultures from the NPM-RAR␣ mouse, mature myeloid cells tended to increase, while, at the same time, immature myeloid cells tended to decrease 24, 48 and 72 h after ATRA treatment. Significant differentiation to maturation was observed 48 h after ATRA treatment, and Gr-1 positive cells increased with time on flow cytometric analysis. On the contrary, BM cells from PLZF-RAR␣ transgenic mice were not inducible for further differentiation (Fig. 3) .
NPM-RAR␣ Bound to RARE. PML-RAR␣ and PLZF-RAR␣ bound to RARE in forms of homodimers or heterodimers with RXR␣, though less efficiently than RAR␣͞ RXR␣ (Fig. 4A) . NPM-RAR␣ also bound to RARE but seemingly not in homodimers. According to the known molecular mass, both PML-RAR␣ and PLZF-RAR␣ monomers and homodimers are Ϸ110 kDa and 220 kDa, respectively, whereas NPM-RAR␣ monomer and homodimer should be Ϸ65 kDa and 130 kDa, respectively. Nevertheless, the NPM-RAR␣ band moved slightly slower than the PML-RAR␣ and PLZF-RAR␣ homodimers (Ϸ220 kDa), suggesting that NPM-RAR␣ could form homotetramer (Ϸ260 kDa). In addition, NPM-RAR␣ formed heterodimer and a variety of other complexes with RXR␣. Shifted bands tended to disappear with increasing concentrations of cognate DR5G, indicating specificity of RARE binding (Fig. 4B) .
Association of NPM-RAR␣ with SMRT in Response to ATRA. In the gel-shift assay, to analyze the interactions between GST-SMRT and wild-type as well as different fusion receptors, RAR␣͞RXR␣, PML-RAR␣, PLZF-RAR␣, and NPM-RAR␣ showed different sensitivities to ATRA. Dissociation of receptors (Fig. 4C , open arrows) from high molecular mass complexes with SMRT (Fig. 4C, solid arrow) occurred at physiological concentrations (0.01 M) for RAR␣͞RXR␣ and at pharmacological concentrations of 0.1 M and 1 M, for NPM-RAR␣ and PML-RAR␣, respectively. However, even in the presence of 10 M ATRA, PLZF-RAR␣ remained associated with SMRT. These results were confirmed by GST pull down. As shown in Fig.  4D , radio-labeled RAR␣, PML-RAR␣, PLZF-RAR␣, and NPM-RAR␣ were retained specifically on the immobilized GST-SMRT without ATRA treatment. However, in the presence of various concentrations of ATRA, these proteins had different ligand sensitivities in binding with GST-SMRT. Notable was the diminished association of SMRT with RAR␣, PML-RAR␣, and NPM-RAR␣ with increasing concentrations of ATRA, whereas PLZF-RAR␣ binding to SMRT remained unchanged at 1 M of ATRA (Fig. 4D) .
DISCUSSION
After initial reports on leukemogenic potential of NPM-RAR␣ in different systems (23-28), we investigated the phenotypes of PLZF-RAR␣ and NPM-RAR␣ transgenic mice and interactions of fusion proteins with RAREs and nuclear corepressors in response to ATRA on a comparative basis. Our results show that both PLZF-RAR␣ and NPM-RAR␣ play an essential role in leukemogenesis and in response to ATRA. However, these two fusion proteins are not identical in their leukemogenic potential.
Leukemia in PLZF-RAR␣ and NPM-RAR␣ Transgenic Mice. He et al. (29) reported that all PLZF-RAR␣ transgenic mice developed CML 6-18 months after birth. In our series, however, five of the hCG-PLZF-RAR␣ transgenic mice developed CMLlike phenotype and died within 3 months after birth; one had a late onset at 11 months. Another striking feature was the growth retardation in early onset mice, which might be due to severe anemia caused by extreme expansion of myeloid cells in hemopoietic tissues. Unlike the accumulation of myeloid blasts blocked at the promyelocyte stage in BM of PML-RAR␣ mice (26-28), (12, 34) . A recent report offered clues for this notion (36) . In transgenic mice expressing the RAR␣-PLZF fusion gene, though no overt leukemia was observed, myelopoiesis was impaired. It is not clear whether there is any synergism between PLZF-RAR␣ and RAR␣-PLZF in cell transformation. Transgenic mice expressing both transcripts of the fusion may clarify this issue. NPM-RAR␣ transgenic mice needed relatively long latent periods to develop leukemia with a spectrum of morphological features. Morphological heterogeneity in mice expressing the same transgene may be the result of an integration positional effect, or some other genetic ''hits'' may be required for the occurrence of full-blown APL. In PML-RAR␣ transgenic mice, however, only APL phenotypes were observed unanimously by several groups (26) (27) (28) ; therefore, a more detailed study is required to identify the true mechanism for phenotypic heterogeneity in NPM-RAR␣ transgenic mice. The different phenotypic features in mice expressing different transgenes may be attributed to the distinct biological properties of the X moiety, the possible effect of the reciprocal transcripts and the positional effect of transgene integration. Nevertheless, our data indicate that both PLZF-RAR␣ and NPM-RAR␣ possess leukemogenic potential.
Abnormal TF expression in APL cells is related to the coagulopathy in APL, though a number of other mechanisms also may be involved (30, 31) . Our results suggest that TF expression may be correlated with expression of X-RAR␣ fusion proteins. Cell lines harboring the translocation t(15;17) or transfected with PML-RAR␣ also expressed TF (37, 38) , suggesting that abnormal TF expression in promyelocytes may be due to novel transcriptional properties acquired by the X-RAR␣ fusion products. Because a number of other tumor cell types also express TF (39), further investigation of the possible specific signaling pathways between TF expression and X-RAR␣ is needed. 
